Two expert MDs say it's a telltale sign that you might be ready for surgery once you start experiencing this type of ...

The Novel Allosteric NEK7 Inhibitor Ofirnoflast (HT-6184) Demonstrates Robust and Sustained Hematologic Response in Subjects with IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndrome ...

Three Cochrane reviews show GLP-1 drugs reduce weight, yet uncertainties remain about long-term safety and equity of access.

How long would you need to jab yourself...and contend with the cost? Two MDs specializing in weight loss and endocrinology share how it works.

(NEXSTAR) — The number of states with high adult obesity rates has dropped for the first time in more than a decade, a new report released Thursday found. The nonprofit Trust for America’s Health ...

Of U.S. adults with a BMI indicating obesity, 98.4% also had excess adiposity confirmed by other measures. Researchers suggest there may be limited utility to confirming excess adiposity in people ...

Please provide your email address to receive an email when new articles are posted on . Most patients with newly diagnosed high-risk myelodysplastic syndrome do not receive guideline-recommended ...

Complications from myelodysplastic syndromes (MDS), like anemia or fatigue, can occur because the bone marrow isn’t making enough healthy or functional blood cells. Myelodysplastic syndromes (MDS) are ...

Myelodysplastic syndromes (MDS) and autoimmune conditions appear to have a two-way connection. Living with one may increase your risk of developing the other. Myelodysplastic syndromes (MDS) are a ...

In the first-line treatment of higher-risk myelodysplastic syndromes (MDS), the combination of venetoclax with azacitidine fell short of the primary endpoint of a reduction in mortality compared with ...